Ampili Jagan

Ampili Jagan practices at William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System.

Ampili Jagan's NPI, 1346620184, was assigned on June 7, 2015. Ampili Jagan holds Texas license AP127802.

Ampili Jagan's primary practice is William P. Clements Jr. University Hospital, at 6201 Harry Hines Blvd, Dallas, TX 75390 in Dallas County. The practice phone is (214) 633-5555.

Ampili Jagan's primary practice is William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System. Ampili Jagan is also affiliated with Parkland Memorial Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Ampili Jagan to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ampili Jagan practices, 4 sites in all. Vendor and product names are available with a free account.

Family is Ampili Jagan's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Ampili Jagan is licensed in Texas.

CMS counts 163 Medicare patients who saw Ampili Jagan in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have diabetes, and 75% have high blood pressure. 17% are also on Medicaid. Their average risk score is 4.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Ampili Jagan's median patient age at 61, with 47% women.

In 2024, Ampili Jagan wrote 577 Medicare Part D claims for 128 patients. 16% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Ampili Jagan for performance year 2024, reported as part of a group. Ampili Jagan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Ampili Jagan as offering telehealth.

CMS Open Payments shows 5 general payments to Ampili Jagan from 4 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $232.